MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$76,156
Net Income
-$314,811
Net Profit Margin
-413.38%
EPS
-$0.118
Unit: Dollar
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue (including nil and 16,109 of revenue from related parties for the three-month period ended june 30, 2026 and 2025, respectively, and nil and 32,179 of revenue from related parties for the six-month period ended june 30, 2026 and 2025, respectively)
76,156
22,842
483,760
2,543,823
Cost of revenue (including nil and 2,307 of cost of revenue from related parties for the three-month period ended june 30, 2026 and 2025, respectively, and nil and 2,307 of cost of revenue from related parties for the six-month period ended june 30, 2026 and 2025, respectively)
63,174
23,632
487,743
2,166,138
Gross profit
12,982
-790
-3,983
377,685
Dividend income
0
0
9,536*
4,192
Interest income
21,183
17,179
9,774
20,778
Fair value gain on investments in equity securities
0
0
-28,256
0
Loss on disposal of investments in equity securities
-
-
46,647*
42,376
Reversal of expected credit losses
-
26,743
49,855
0
Gain from foreign exchange
-
5,617
23,666*
-
Reversal of expected credit losses
91,383
-
-
-
Gain from foreign exchange
46
-
-
-
Others
8,393
8,147
-87,746
40,414
Total other income
121,005
57,686
23,476
107,760
Sales and marketing
36,022
52,733
-3,663*
551,569
Research and development
13,671
14,487
9,520.5*
14,876
General and administrative (including nil and 1,012 of rental expenses to related party for the three-month period ended june 30, 2026 and 2025, respectively, and nil and 2,056 of rental expenses to related party for the six-month period ended june 30, 2026 and 2025, respectively)
298,526
327,669
91,730.5*
445,691
Share-based compensation
-
-
198,692.5*
-
Fair value loss on investments in equity securities
0
0
93,965*
0
Provision for expected credit gaines
68,164
202,497
2,768,754.5*
175,818
Total operating expenses
416,383
597,386
3,159,000
1,187,954
Loss from operations
-282,396
-540,490
-1,032,845
-702,509
Finance costs
4,055
3,085
3,272
6,482
Loss before tax
-286,451
-543,575
-1,036,117
-708,991
Deferred tax
-
-
0*
-
Income tax
-
-
0*
-
Tax expense
0
-
0
0
Net loss attributable to common shareholders
-286,451
-543,575
-1,036,117
-708,991
Foreign currency translation loss
-
21,900
-8,202
3,216
Foreign currency translation (loss)/gain
-28,360
-
-
-
Comprehensive loss
-314,811
-521,675
-1,044,319
-705,775
Diluted EPS
-0.118
-0.225
-
-0.395
Diluted Average Shares
2,417,314
2,417,314
-
1,796,597
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive loss-$314,811 (-26.38%↓ Y/Y)Net lossattributable to common...-$286,451 (53.51%↑ Y/Y)Foreign currencytranslation (loss)/gain-$28,360 Loss before tax-$286,451 (53.51%↑ Y/Y)Reversal of expectedcredit losses$91,383 (31.00%↑ Y/Y)Interest income$21,183 (-28.84%↓ Y/Y)Others$8,393 (-89.18%↓ Y/Y)Gain from foreignexchange$46 Revenue (including niland 16,109 of...$76,156 (-96.63%↓ Y/Y)Loss from operations-$282,396 (53.80%↑ Y/Y)Finance costs$4,055 (-16.89%↓ Y/Y)Total other income$121,005 (-42.23%↓ Y/Y)Gross profit$12,982 (-96.47%↓ Y/Y)Cost of revenue(including nil and 2,307 of...$63,174 (-96.66%↓ Y/Y)Total operatingexpenses$416,383 (-64.97%↓ Y/Y)General andadministrative (including nil...$298,526 (-42.23%↓ Y/Y)Provision for expectedcredit gaines$68,164 Sales and marketing$36,022 (-94.08%↓ Y/Y)Research and development$13,671 (8.87%↑ Y/Y)

BioNexus Gene Lab Corp (BGLC)

BioNexus Gene Lab Corp (BGLC)